{
    "clinical_study": {
        "@rank": "8306", 
        "arm_group": {
            "arm_group_label": "GZ402665", 
            "arm_group_type": "Experimental", 
            "description": "GZ402665 dose (0,3; 1,0 or 3,0 mg/kg body weight) once every 2 weeks for 5 years"
        }, 
        "brief_summary": {
            "textblock": "The primary objective of this study is to obtain data regarding the ongoing safety of\n      recombinant human acid sphingomyelinase (rhASM) in patients with acid sphingomyelinase\n      deficiency (ASD) who are exposed to long-term treatment with rhASM\n\n      The secondary objectives of this study are to obtain data regarding the efficacy of rhASM\n      and to characterize rhASM pharmacodynamics and pharmacokinetics following long-term\n      administration."
        }, 
        "brief_title": "A Long-Term Study of Recombinant Human Acid Sphingomyelinase in Patients With Acid Sphingomyelinase Deficiency", 
        "completion_date": {
            "#text": "March 2021", 
            "@type": "Anticipated"
        }, 
        "condition": "Sphingomyelin Lipidosis", 
        "condition_browse": {
            "mesh_term": [
                "Lipidoses", 
                "Niemann-Pick Diseases", 
                "Niemann-Pick Disease, Type A", 
                "Niemann-Pick Disease, Type C"
            ]
        }, 
        "detailed_description": {
            "textblock": "One month screening + 60 months from the first dose + 30 to 37 days post study safety follow\n      up"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion criteria :\n\n          -  The patient has completed the treatment period of a previous study of rhASM with an\n             acceptable safety profile.\n\n          -  Negative serum pregnancy test.\n\n          -  Patients must practice true abstinence or use 2 effective forms of contraception\n\n        Exclusion criteria:\n\n          -  The patient is breast-feeding.\n\n          -  ALT or AST >250 IU/L or total bilirubin >1.5 mg/dL.\n\n          -  The patient is unwilling or unable to abstain from the use of alcohol for 1 day prior\n             to and 3 days after each rhASM infusion for the duration of the study.\n\n          -  The patient requires medications that may decrease rhASM\n\n          -  Any new condition or worsening of an existing condition which in the opinionof the\n             Investigator would make the patient unsuitable for enrollment, or could interfere\n             with the patient participating in or completing the study.\n\n        The above information is not intended to contain all considerations relevant to a\n        patient's potential participation in a clinical trial."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "70", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 26, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02004704", 
            "org_study_id": "LTS13632", 
            "secondary_id": [
                "2013-000051-40", 
                "U1111-1141-65868"
            ]
        }, 
        "intervention": {
            "arm_group_label": "GZ402665", 
            "description": "Pharmaceutical form:Powder for concentrate for solution for infusion\nRoute of administration: intravenous infusion", 
            "intervention_name": "GZ402665", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "June 4, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10029-6574"
                    }, 
                    "name": "Investigational Site Number 840001"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "London", 
                        "country": "United Kingdom", 
                        "zip": "WC1N 3BG"
                    }, 
                    "name": "Investigational Site Number 826001"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "United Kingdom"
            ]
        }, 
        "number_of_arms": "1", 
        "official_title": "A Long-Term Study to Assess the Ongoing Safety and Efficacy of Recombinant Human Acid Sphingomyelinase in Patients With Acid Sphingomyelinase Deficiency", 
        "overall_contact": {
            "email": "Contact-Us@sanofi.com", 
            "last_name": "For site information, send an email with site number to"
        }, 
        "overall_official": {
            "affiliation": "Sanofi", 
            "last_name": "Clinical Sciences & Operations", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "March 2021", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Number of patients experience AE", 
                "measure": "All Adverse events and Serious Adverse Events", 
                "safety_issue": "Yes", 
                "time_frame": "Baseline to Week 272"
            }, 
            {
                "measure": "Physical examinations", 
                "safety_issue": "Yes", 
                "time_frame": "Baseline to Week 272"
            }, 
            {
                "measure": "Clinical laboratory tests", 
                "safety_issue": "Yes", 
                "time_frame": "Baseline to Week 272"
            }, 
            {
                "measure": "Safety biomarkers", 
                "safety_issue": "Yes", 
                "time_frame": "Baseline to Week 272"
            }, 
            {
                "measure": "Immune response assessments", 
                "safety_issue": "Yes", 
                "time_frame": "Baseline to Week 272"
            }, 
            {
                "measure": "Vital signs, echocardiogram and electrocardiogram", 
                "safety_issue": "No", 
                "time_frame": "Baseline to Week 272"
            }, 
            {
                "measure": "Continuous heart rate monitoring by telemetry (in-patients visits)", 
                "safety_issue": "Yes", 
                "time_frame": "Baseline to Week 272"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02004704"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Spleen and Liver Volume", 
                "safety_issue": "No", 
                "time_frame": "Baseline to Week 272"
            }, 
            {
                "measure": "Pulmonary imaging and function tests", 
                "safety_issue": "No", 
                "time_frame": "Baseline to Week 272"
            }, 
            {
                "measure": "Exercise capacity by cycle ergometry", 
                "safety_issue": "No", 
                "time_frame": "Baseline to Week 272"
            }, 
            {
                "measure": "Hematology", 
                "safety_issue": "No", 
                "time_frame": "Baseline to Week 272"
            }
        ], 
        "source": "Sanofi", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Genzyme, a Sanofi Company", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "June 2014"
    }
}